文献速递乳腺癌

来曲唑联合哌柏西利对比化疗用于高危Luminal乳腺癌新辅助治疗的II期研究

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer.
PubMed 文献 · Ann Oncol · 2018-01-01

NeoPAL研究为随机非比较II期试验,纳入106例ER阳性/HER2阴性、Prosigna定义的高危Luminal B或Luminal A伴淋巴结阳性、不适合保乳的II-III期乳腺癌患者。来曲唑-哌柏西利(LETPAL)组与化疗组RCB 0-I率分别为7.7%和15.7%,pCR率分别为3.8%和5.9%,临床缓解率与保乳率相似,LETPAL组严重不良事件更少。

要点

  • LETPAL组RCB 0-I率7.7%(95%CI 0.4-14.9),化疗组15.7%(95%CI 5.7-25.7)。
  • LETPAL组严重不良事件2例,化疗组17例(含11例4级严重AE)。
  • LETPAL病理反应差但临床和生物标志物反应令人鼓舞,或可替代化疗。

核心结论

  • LETPAL联合方案在高危Luminal乳腺癌中病理反应差但临床和生物标志物反应令人鼓舞,或可成为早期高危Luminal乳腺癌化疗的替代选择。

研究设计与样本

  • NeoPAL(UCBG10/4,NCT02400567)为随机、平行、非比较II期研究,共随机106例患者。
  • 入组标准为ER阳性、HER2阴性、Prosigna定义Luminal B或Luminal A伴淋巴结阳性、II-III期、不适合保乳手术的乳腺癌患者。
  • LETPAL组接受来曲唑2.5 mg每日联合哌柏西利125 mg每日(服3周停1周)共19周;化疗组接受FEC100×3周期(21天/周期)序贯多西他赛100 mg/m2×3周期(21天/周期)。
  • 主要终点为残余肿瘤负荷(RCB 0-I率),次要终点包括临床缓解、增殖相关标志物和安全性。

主要发现

  • LETPAL组4例(7.7%,95%CI 0.4-14.9)达RCB 0-I,化疗组8例(15.7%,95%CI 5.7-25.7)。
  • LETPAL组和化疗组病理完全缓解率分别为3.8%和5.9%。
  • 两组临床缓解率(75%)和保乳手术率(69%)相似。
  • 术前内分泌预后指数(PEPI)0分者在LETPAL组和化疗组分别为17.6%和8.0%。
  • LETPAL组严重不良事件2例,化疗组17例(包括化疗组11例4级严重不良事件)。

临床怎么用

  • 对于Prosigna定义的高危Luminal乳腺癌、不适合保乳手术的患者,LETPAL联合方案病理反应较差但临床和生物标志物反应令人鼓舞,安全性优于化疗,或可作为化疗的替代选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Palbociclib is a CDK4/6 inhibitor with demonstrated efficacy and safety in combination with endocrine therapy in advanced luminal breast cancer (LBC). We evaluated the respective efficacy and safety of chemotherapy and letrozole-palbociclib (LETPAL) combination as neoadjuvant treatment in patients with high-risk LBC. PATIENTS AND METHODS: NeoPAL (UCBG10/4, NCT02400567) is a randomised, parallel, non-comparative phase II study. Patients with ER-positive, HER2-negative, Prosigna®-defined luminal B, or luminal A and node-positive, stage II-III breast cancer, not candidate for breast-conserving surgery, were randomly assigned to either letrozole (2.5 mg daily) and palbociclib (125 mg daily, 3 weeks/4) during 19 weeks, or to FEC100 (5FU 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2)×3 21-day courses followed by docetaxel 100 mg/m2×3 21-day courses. Primary end point was residual cancer burden (RCB 0-I rate). Secondary end points included clinical response, proliferation-based markers, and safety. RESULTS: Overall, 106 patients were randomised [median Prosigna® ROR Score 71 (22-93)]. RCB 0-I was observed in four and eight patients in LETPAL [7.7% (95% CI 0.4-14.9)] and chemotherapy [15.7% (95% CI 5.7-25.7)] arms, respectively. Pathological complete response rates were 3.8% and 5.9%. Clinical response (75%) and breast-conserving surgery rates (69%) were similar in both arms. Preoperative Endocrine Prognostic Index 0 scores (breast cancer-specific survival) were observed in 17.6% and 8.0% of patients in LETPAL and chemotherapy arms, respectively. Safety profile was as expected, with 2 versus 17 serious adverse events (including 11 grade 4 serious AEs in the chemotherapy arm). CONCLUSION: LETPAL combination was associated with poor pathological response but encouraging clinical and biomarker responses in Prosigna®-defined high-risk LBC. Contemporary chemotherapy regimen was associated with poor pathological and biomarker responses, with a much less favourable safety profile. LETPAL combination might represent an alternative to chemotherapy in early high-risk LBC. CLINICAL TRIAL NUMBER: NCT02400567.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Cottu P, D'Hondt V, Dureau S, et al. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Ann Oncol. 2018. PMID: 30307466. doi:10.1093/annonc/mdy448

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。